儿童银屑病与COVID-19:不良COVID-19病程相关因素及感染对疾病进展的影响(Chi-PsoCov登记研究)
国际登记研究纳入117名儿童(平均12.4岁)共120次COVID-19发作,评估感染对银屑病的影响及与系统治疗相关的感染严重程度。生物制剂组COVID-19症状持续时间显著短于非生物制剂系统治疗组(P=0.02)和无系统治疗组(P=0.006);住院的6名儿童更常见于非生物制剂系统治疗(P=0.01),尤其甲氨蝶呤(P=0.03)。感染后银屑病加重17例(15.2%),9名儿童(8%)在感染后1个月内新发银屑病,主要为滴状型(P=0.01)。
要点
- 生物制剂组COVID-19症状持续时间显著短于非生物制剂系统治疗组(P=0.02)和无系统治疗组(P=0.006)。
- 住院的6名儿童更常见于非生物制剂系统治疗(P=0.01),尤其甲氨蝶呤(P=0.03)。
- 感染后银屑病加重17例(15.2%),9名儿童(8%)新发银屑病,主要为滴状型(P=0.01)。
核心结论
- 生物制剂在儿童银屑病患者中似乎安全,不增加严重COVID-19风险。
- COVID-19导致部分儿童新发银屑病或已知银屑病加重。
研究设计与样本
- 国际儿童银屑病登记研究,纳入117名18岁以下有银屑病病史或COVID-19后1个月内发生银屑病且患COVID-19(有或无症)的儿童,共120次COVID-19发作。
主要发现
- 120次COVID-19发作中,斑块型银屑病占69.4%;54.2%无系统治疗,33名(28.3%)使用生物制剂,24名(20%)使用非生物制剂系统药物。
- COVID-19确诊106名(88.3%),75名(62.5%)有症状,平均持续时间6.5天;非生物制剂系统治疗组(P=0.02)和无系统治疗组(P=0.006)症状持续时间显著长于生物制剂组。
- 住院的6名儿童更常见于非生物制剂系统治疗(P=0.01),尤其甲氨蝶呤(P=0.03)。
- 感染后银屑病加重17例(15.2%);9名儿童(8%)在COVID-19后1个月内新发银屑病,主要为滴状型(P=0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The COVID-19 pandemic has raised questions regarding the management of chronic skin diseases, especially in patients on systemic treatments. Data concerning the use of biologics in adults with psoriasis are reassuring, but data specific to children are missing. Moreover, COVID-19 could impact the course of psoriasis in children. OBJECTIVES: The aim of this study was therefore to assess the impact of COVID-19 on the psoriasis of children, and the severity of the infection in relation to systemic treatments. METHODS: We set up an international registry of paediatric psoriasis patients. Children were included if they were under 18 years of age, had a history of psoriasis, or developed it within 1 month of COVID-19 and had COVID-19 with or without symptoms. RESULTS: One hundred and twenty episodes of COVID-19 in 117 children (mean age: 12.4 years) were reported. The main clinical form of psoriasis was plaque type (69.4%). Most children were without systemic treatment (54.2%); 33 (28.3%) were on biologic therapies, and 24 (20%) on non-biologic systemic drugs. COVID-19 was confirmed in 106 children (88.3%) and 3 children had two COVID-19 infections each. COVID-19 was symptomatic for 75 children (62.5%) with a mean duration of 6.5 days, significantly longer for children on non-biologic systemic treatments (P = 0.02) and without systemic treatment (P = 0.006) when compared with children on biologics. The six children who required hospitalization were more frequently under non-biologic systemic treatment when compared with the other children (P = 0.01), and particularly under methotrexate (P = 0.03). After COVID-19, the psoriasis worsened in 17 cases (15.2%). Nine children (8%) developed a psoriasis in the month following COVID-19, mainly a guttate form (P = 0.01). DISCUSSION: Biologics appear to be safe with no increased risk of severe form of COVID-19 in children with psoriasis. COVID-19 was responsible for the development of psoriasis or the worsening of a known psoriasis for some children.
引用
- Zitouni J, Bursztejn AC, Belloni Fortina A, et al. Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry). J Eur Acad Dermatol Venereol. 2022. PMID: 35748102. doi:10.1111/jdv.18361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。